IDH1 and biliary tract cancer: This has also been reported in two contemporary randomised clinical trials, exploring the role of regorafenib (multi-tyrosine kinase inhibitor)29 and ivosidenib (IDH1 inhibitor)17 in the second-line setting for patients with advanced biliary tract cancer.